CIBS Network

CIBS_newtork.jpg
 

Innovating Together

In line with our mission to create innovations in brain science of the future for those who need a cure today, we believe that academic researchers must ensure that their discoveries move from the laboratory bench to the patients’ bedside as quickly as possible. Supported by in-house regulatory and intellectual property experts, as well as Tech Launch Arizona, many CIBS investigators have launched companies to further advance the development of their therapeutics.

 
R_logo.jpg

RASRx, cofounded by Dr's Rodgers and Gaffney, is dedicated to delivering cutting-edge therapeutics for Duchenne Muscular Dystrophy as well as a host of inflammatory and orphan diseases. The RASRx approach is focused on harnessing the body's own regenerative processes.

 
regulonix.jpg

Regulonix is dedicated to developing novel non-opioid therapeutics for chronic pain. Focusing on non-traditional, sodium channel targets, the team (including Dr. May Khanna) was able to demonstrate their compound to be more effective than morphine, non-addictive, and non-toxic.